person · Reporting owner
RA Capital Nexus Fund III, L.P.
Disclosed activity across 10 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director | June 09, 2026 | June 10, 2026 |
| Climb Bio, Inc.CLYM · Entity 5064 | Director | September 28, 2026 | October 01, 2026 |
| Evommune, Inc.EVMN · Entity 5539 | Director | February 17, 2026 | February 18, 2026 |
| Freenome, Inc.FRNM · Entity 4644 | Director | July 20, 2026 | July 22, 2026 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | March 27, 2026 | March 31, 2026 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | July 20, 2026 | July 22, 2026 |
| Septerna, Inc.SEPN · Entity 2452 | Director | August 12, 2026 | August 14, 2026 |
| Sionna Therapeutics, Inc.SION · Entity 5996 | Director | September 17, 2026 | September 21, 2026 |
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Director | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | IndirectSee Footnotes | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein. F3: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.
F3: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Bicara Therapeutics Inc.
Report date June 09, 2026 · Filed June 10, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09 | IndirectSee Footnotes | 19,475 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475 F1: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2027, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2027, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Climb Bio, Inc.
Report date September 28, 2026 · Filed October 01, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 10,000 |
Reported balance
After 2026-09-28 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-09-28 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 20,000 |
Reported balance
After 2026-09-28 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-09-28 · Exercise / conversion · Acquired 10,000 · Balance 20,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 30,000 |
Reported balance
After 2026-09-28 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-09-28 · Exercise / conversion · Acquired 10,000 · Balance 30,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 70,000 |
Reported balance
After 2026-09-28 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-09-28 · Exercise / conversion · Acquired 40,000 · Balance 70,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,837,101 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,837,101 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: These securities are held directly by Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,226,497 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,226,497 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4: These securities are held directly by the Nexus Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 483,679 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 483,679 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F5: These securities are held directly by the Nexus Fund II. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,671,766 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 3,671,766 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F6: These securities are held directly by Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 841,087 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 841,087 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F7: These securities are held directly by the Account. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 · Expires 2026-09-29 | IndirectSee footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-28 · Exercise / conversion · Disposed 10,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-09-29 | IndirectSee Footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-28 · Exercise / conversion · Disposed 10,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2026-09-29 | IndirectSee Footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-28 · Exercise / conversion · Disposed 10,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2026-09-29 | IndirectSee Footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-28 · Exercise / conversion · Disposed 40,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
F3: These securities are held directly by Fund.
F4: These securities are held directly by the Nexus Fund.
F5: These securities are held directly by the Nexus Fund II.
F6: These securities are held directly by Nexus Fund III.
F7: These securities are held directly by the Account.
F8: Immediately exercisable.
Evommune, Inc.
Report date February 17, 2026 · Filed February 18, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,710,293 |
Reported balance
After 2026-02-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 35,868 · Balance 2,710,293 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 784,345 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 784,345 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F2: Held directly by the Fund.
F3: Held directly by the Nexus Fund III.
Freenome, Inc.
Report date July 20, 2026 · Filed July 22, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 7,311,711 |
Reported balance
After 2026-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-07-20 · Grant · Acquired 6,561,711 · Balance 7,311,711 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F2: Received in the Business Combination in exchange for 4,886,446 shares of Series B Preferred Stock, 4,111,335 shares of Series C Preferred Stock, 4,093,925 shares of Series D Preferred Stock and 10,103,180 shares of Series F Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 970,950 |
Reported balance
After 2026-07-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-07-20 · Grant · Acquired 970,950 · Balance 970,950 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F5: Received in the Business Combination in exchange for 1,920,093 shares of Series B Preferred Stock and 1,512,104 shares of Series C Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F6: Held directly by the Nexus Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 553,703 |
Reported balance
After 2026-07-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-07-20 · Grant · Acquired 553,703 · Balance 553,703 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F7: Received in the Business Combination in exchange for 1,754,539 shares of Series D Preferred Stock and 202,739 shares of Series F Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F8: Held directly by Nexus Fund II. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 908,103 |
Reported balance
After 2026-07-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-07-20 · Grant · Acquired 908,103 · Balance 908,103 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F9: Received in the Business Combination in exchange for 3,210,040 shares of Series F Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F10: Held directly by Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 367,427 |
Reported balance
After 2026-07-20 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-07-20 · Grant · Acquired 367,427 · Balance 367,427 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F11: Received in the Business Combination in exchange for 873,834 shares of Series B Preferred Stock and 424,978 shares of Series C Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F12: Held directly by the Account. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 12,230,122 |
Reported balance
After 2026-07-20 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2026-07-20 · Grant · Acquired 4,918,411 · Balance 12,230,122 F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,245,068 |
Reported balance
After 2026-07-20 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2026-07-20 · Grant · Acquired 336,965 · Balance 1,245,068 F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F10: Held directly by Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination").
F2: Received in the Business Combination in exchange for 4,886,446 shares of Series B Preferred Stock, 4,111,335 shares of Series C Preferred Stock, 4,093,925 shares of Series D Preferred Stock and 10,103,180 shares of Series F Preferred Stock of Old Freenome.
F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F4: Held directly by the Fund.
F5: Received in the Business Combination in exchange for 1,920,093 shares of Series B Preferred Stock and 1,512,104 shares of Series C Preferred Stock of Old Freenome.
F6: Held directly by the Nexus Fund.
F7: Received in the Business Combination in exchange for 1,754,539 shares of Series D Preferred Stock and 202,739 shares of Series F Preferred Stock of Old Freenome.
F8: Held directly by Nexus Fund II.
F9: Received in the Business Combination in exchange for 3,210,040 shares of Series F Preferred Stock of Old Freenome.
F10: Held directly by Nexus Fund III.
F11: Received in the Business Combination in exchange for 873,834 shares of Series B Preferred Stock and 424,978 shares of Series C Preferred Stock of Old Freenome.
F12: Held directly by the Account.
Mineralys Therapeutics, Inc.
Report date March 27, 2026 · Filed March 31, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,767,221 |
Reported balance
After 2026-03-27 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-03-27 · Purchase · Acquired 310,700 · Balance 5,767,221 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.31 to $24.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,825,521 |
Reported balance
After 2026-03-30 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-03-30 · Purchase · Acquired 58,300 · Balance 5,825,521 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,867,229 |
Reported balance
Holding disclosure · report date 2026-03-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,867,229 F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5: Held directly by Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.31 to $24.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").
F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5: Held directly by Nexus Fund III.
Parabilis Medicines, Inc.
Report date July 20, 2026 · Filed July 22, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,383,526 |
Reported balance
After 2026-07-20 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-07-20 · Purchase · Acquired 98,433 · Balance 26,383,526 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.53 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,416,513 |
Reported balance
After 2026-07-20 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-07-20 · Purchase · Acquired 32,987 · Balance 26,416,513 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.55 to $27.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,438,209 |
Reported balance
After 2026-07-21 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-07-21 · Purchase · Acquired 21,696 · Balance 26,438,209 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.46 to $28.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,444,713 |
Reported balance
After 2026-07-21 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-07-21 · Purchase · Acquired 6,504 · Balance 26,444,713 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.83 to $29.79 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,482,436 |
Reported balance
After 2026-07-21 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-07-21 · Purchase · Acquired 37,723 · Balance 26,482,436 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.97 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,529,686 |
Reported balance
After 2026-07-22 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-07-22 · Purchase · Acquired 47,250 · Balance 26,529,686 F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.35 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,648,278 |
Reported balance
Holding disclosure · report date 2026-07-20 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,648,278 F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F9: Held directly by Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.53 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3: Held directly by the Fund.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.55 to $27.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.46 to $28.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.83 to $29.79 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.97 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.35 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F9: Held directly by Nexus Fund III.
Septerna, Inc.
Report date August 12, 2026 · Filed August 14, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,777,415 |
Reported balance
After 2026-08-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 746,500 · Balance 4,777,415 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 725,443 |
Reported balance
After 2026-08-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-08-12 · Sale · Disposed 746,500 · Balance 725,443 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F2: Held directly by the Fund.
F3: Held directly by the Nexus Fund III.
Sionna Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,482,612 |
Reported balance
After 2026-09-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-09-17 · Sale · Disposed 3,415,011 · Balance 3,482,612 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,448,812 |
Reported balance
After 2026-09-17 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-09-17 · Sale · Disposed 33,800 · Balance 3,448,812 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 650,307 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 650,307 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,198,082 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,198,082 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5: Held directly by the Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 159,033 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 159,033 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6: Held directly by the Account. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2: Held directly by the Fund.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Held directly by the Nexus Fund.
F5: Held directly by the Nexus Fund III.
F6: Held directly by the Account.
SpyGlass Pharma, Inc.
Report date February 09, 2026 · Filed February 11, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,524,473 |
Reported balance
After 2026-02-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-09 · Conversion · Acquired 2,524,473 · Balance 2,524,473 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,806,644 |
Reported balance
After 2026-02-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-02-09 · Conversion · Acquired 1,806,644 · Balance 1,806,644 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,966,439 |
Reported balance
After 2026-02-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-02-09 · Purchase · Acquired 3,441,966 · Balance 5,966,439 F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,054,678 |
Reported balance
After 2026-02-09 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-02-09 · Purchase · Acquired 248,034 · Balance 2,054,678 F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-09 · Conversion · Disposed 1,150,941 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-09 · Conversion · Disposed 767,294 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Series C-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-09 · Conversion · Disposed 1,150,941 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Series C-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-09 · Conversion · Disposed 767,294 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-09 · Conversion · Disposed 222,591 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-09 · Conversion · Disposed 272,056 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3: Held directly by the Fund.
F4: Held directly by the Nexus Fund III.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 22:57 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionSeries E Preferred Stock · Derivative | 642,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000638 · form4-06152026_100639.xml · derivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Voting Common Stock · 419,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date. F1 · price: Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date. F1 · derivative.exercise_date: Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4 · ownership.nature: Held directly by the Fund. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 22:57 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | PurchaseVoting Common Stock | 1,460,397 | $20.00 | $29,207,940.00 |
DisclosureSEC source: 0001231919-26-000638 · form4-06152026_100639.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,648,278 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F5 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 22:57 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | PurchaseVoting Common Stock | 19,728,353 | $20.00 | $394,567,060.00 |
DisclosureSEC source: 0001231919-26-000638 · form4-06152026_100639.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 26,285,093 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4 · ownership.nature: Held directly by the Fund. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 22:57 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionVoting Common Stock | 1,187,881 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000638 · form4-06152026_100639.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,187,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date. F2 · price: Each share of Series F Preferred Stock automatically converted into shares of Voting Common Stock on a 1 to 0.6498 basis immediately prior to the closing of the IPO and without payment of consideration. The Series F Preferred Stock has no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F5 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 22:57 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionVoting Common Stock | 6,556,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000638 · form4-06152026_100639.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,556,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series E Preferred Stock automatically converted into Voting Common Stock on a 1 to 0.6524 basis immediately prior to the closing of the IPO and without payment of consideration. The Series E Preferred Stock has no expiration date. F2 · price: Each share of Series F Preferred Stock automatically converted into shares of Voting Common Stock on a 1 to 0.6498 basis immediately prior to the closing of the IPO and without payment of consideration. The Series F Preferred Stock has no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4 · ownership.nature: Held directly by the Fund. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 23:36 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | PurchaseCommon Stock | 103 | $7.00 | $721.00 |
DisclosureSEC source: 0001231919-26-000625 · form4-06112026_110625.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 15,683,137 F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 20:43 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 19,475 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001231919-26-000618 · form4-06102026_080603.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 19,475 Underlying: Common Stock · 19,475 shares Expires 2036-06-09 F1 · derivative.exercise_date: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2027, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 23:36 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | PurchaseCommon Stock | 479,039 | $6.91 | $3,310,159.49 |
DisclosureSEC source: 0001231919-26-000625 · form4-06112026_110625.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 15,683,034 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.77 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 22:36 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | GrantStock Option (Right to Buy) · Derivative | 20,215 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000623 · form4-06112026_100601.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 20,215 Underlying: Common Stock · 20,215 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to Dr. Simson's continued service on such vesting date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:57 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001231919-26-000610 · form4-06082026_100640.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| May 11, 2026 Filed May 13, 2026 21:45 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 2,170,138 | $11.52 Strike: $0.00 | $24,999,772.75 |
DisclosureSEC source: 0001231919-26-000491 · form4-05132026_090548.xml · derivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,170,138 Underlying: Common Stock · 2,170,138 shares Expires not disclosed F6 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F6 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2 · ownership.nature: Held directly by the Fund. Read SEC document |
| May 11, 2026 Filed May 13, 2026 21:45 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | PurchaseCommon Stock | 6,510,416 | $11.52 | $74,999,992.32 |
DisclosureSEC source: 0001231919-26-000491 · form4-05132026_090548.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 15,203,995 F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2 · ownership.nature: Held directly by the Fund. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 22:46 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantPre-Funded Warrants (Right to Buy) · Derivative | 2,106,000 | $9.50 Strike: $0.00 | $20,006,789.40 |
DisclosureSEC source: 0001231919-26-000429 · form4-04292026_100401.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 22,546,000 Underlying: Common Stock · 2,106,000 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 58,300 | $24.16 | $1,408,528.00 |
DisclosureSEC source: 0001231919-26-000300 · form4-03312026_040301.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,825,521 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 310,700 | $23.67 | $7,354,269.00 |
DisclosureSEC source: 0001231919-26-000300 · form4-03312026_040301.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,767,221 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.31 to $24.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:22 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 2,200,000 | $16.00 Strike: $0.00 | $35,199,780.00 |
DisclosureSEC source: 0001231919-26-000231 · form4-03022026_090351.xml · derivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,200,000 Underlying: Common Stock · 2,200,000 shares Expires not disclosed F4 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F4 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:22 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | PurchaseCommon Stock | 300,000 | $16.00 | $4,800,000.00 |
DisclosureSEC source: 0001231919-26-000231 · form4-03022026_090351.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,603,418 F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:49 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option (Right to Buy) · Derivative | 8,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001231919-26-000186 · form4-02212026_120253.xml · derivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F6 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs and the options for the benefit of the Fund and the Nexus Fund III. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:49 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000186 · form4-02212026_120253.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,200 F1 · shares: Restricted Stock Units (RSUs) are granted to Dr. Derek DiRocco for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs and the options for the benefit of the Fund and the Nexus Fund III. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:28 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantCommon Stock | 35,868 | $27.88 | $999,999.84 |
DisclosureSEC source: 0001231919-26-000164 · form4-02182026_120251.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,710,293 F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionSeries D Preferred Stock · Derivative | 272,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · derivative · entry 10 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 272,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionSeries D Preferred Stock · Derivative | 222,591 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · derivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 222,591 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionSeries C-2 Preferred Stock · Derivative | 767,294 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · derivative · entry 8 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 767,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionSeries C-2 Preferred Stock · Derivative | 1,150,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · derivative · entry 7 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,150,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionSeries C-1 Preferred Stock · Derivative | 767,294 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · derivative · entry 6 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 767,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionSeries C-1 Preferred Stock · Derivative | 1,150,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · derivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,150,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | PurchaseCommon Stock | 248,034 | $16.00 | $3,968,544.00 |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,054,678 F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | PurchaseCommon Stock | 3,441,966 | $16.00 | $55,071,456.00 |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,966,439 F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionCommon Stock | 1,806,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,806,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:15 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | ConversionCommon Stock | 2,524,473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000135 · form4-02112026_100217.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,524,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Fund. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:05 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | GrantStock Option (right to buy) · Derivative | 27,400 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000122 · form4-02092026_100237.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2036-02-05 F1 · derivative.exercise_date: This option was granted to Dr. Zachary Scheiner pursuant to the Issuer's non-employee director compensation policy. Subject to Dr. Scheiner's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026. F1 · ownership.nature: This option was granted to Dr. Zachary Scheiner pursuant to the Issuer's non-employee director compensation policy. Subject to Dr. Scheiner's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Scheiner,'s arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:55 UTC | Climb Bio, Inc. CLYM · Entity 5064 | PurchaseCommon Stock | 7,111 | $3.50 | $24,888.50 |
DisclosureSEC source: 0001231919-26-000018 · form4-01072026_090137.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,403,429 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.495 to $3.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 00:55 UTC | Climb Bio, Inc. CLYM · Entity 5064 | PurchaseCommon Stock | 101,462 | $2.86 | $290,181.32 |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,396,318 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $3.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:55 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantPre-Funded Warrants (Right to Buy) · Derivative | 20,440,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · derivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 20,440,000 Underlying: Common Stock · 20,440,000 shares Expires not disclosed F1 · kind: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share. F1 · price: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share. F11 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F11 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:55 UTC | Climb Bio, Inc. CLYM · Entity 5064 | PurchaseCommon Stock | 213,099 | $2.18 | $464,555.82 |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,294,856 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:55 UTC | Climb Bio, Inc. CLYM · Entity 5064 | Disposition to issuerCommon Stock | 20,440,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,081,757 F1 · kind: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 7,609 | $39.50 | $300,555.50 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 12 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 159,033 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 6,440 | $39.50 | $254,380.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 11 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,198,082 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 9,924 | $39.50 | $391,998.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 10 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 650,307 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 1,210 | $39.50 | $47,795.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,897,623 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 604 | $40.50 | $24,462.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 8 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 166,642 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $40.51 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 512 | $40.50 | $20,736.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 7 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,204,522 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $40.51 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 788 | $40.50 | $31,914.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 6 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 660,231 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $40.51 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 96 | $40.50 | $3,888.00 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,898,833 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $40.51 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 947 | $39.89 | $37,775.83 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 167,246 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 801 | $39.89 | $31,951.89 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,205,034 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 1,235 | $39.89 | $49,264.15 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 661,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 150 | $39.89 | $5,983.50 |
DisclosureSEC source: 0001231919-25-000547 · form4-11242025_101109.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,898,929 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 9 | $40.61 | $365.49 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 24 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 168,193 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 8 | $40.61 | $324.88 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 23 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,205,835 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.